Moreover, post-treatment tumor biopsies from responders had lower Treg infiltration than lesions from non-responder patients and the authors hypothesized that this could be explained by the increased presence of FcγR “inflammatory” macrophages capable of inducing ADCC in the presence of the IgG1 Ipilimumab antibody and depleting Tregs (119). The gene discussed is FCGR2A; the disease is neoplasm.